SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases

The treatments, known as SRP-1001 and SRP-1003, are under investigation for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively.
In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
Profile Image
Shivani Kumaresan·Stocktwits
Published Mar 25, 2026   |   8:50 AM EDT
Share
·
Add us onAdd us on Google

Sarepta Therapeutics Inc. (SRPT) on Wednesday released initial results from two investigational programs targeting genetic muscle diseases, demonstrating encouraging safety and biological activity in early trials.

The findings suggest the company’s approach may overcome longstanding delivery challenges in RNA therapies.

The therapies, identified as SRP-1001 and SRP-1003, are being studied for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively. 

Following the update, Sarepta stock traded over 3% higher in Wednesday’s premarket. 

Get updates to this developing story directly on Stocktwits.

Follow on Google News
Read about our editorial guidelines and ethics policy